Compare UTG & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTG | LGND |
|---|---|---|
| Founded | 2003 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | UTG | LGND |
|---|---|---|
| Price | $36.67 | $198.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $239.33 |
| AVG Volume (30 Days) | ★ 317.8K | 223.2K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 7.28% | N/A |
| EPS Growth | N/A | ★ 0.76 |
| EPS | ★ 9.86 | 2.49 |
| Revenue | $96,107,593.00 | ★ $251,233,000.00 |
| Revenue This Year | N/A | $52.87 |
| Revenue Next Year | N/A | $6.07 |
| P/E Ratio | ★ $3.20 | $79.16 |
| Revenue Growth | 8.35 | ★ 64.83 |
| 52 Week Low | $25.26 | $93.58 |
| 52 Week High | $35.29 | $212.49 |
| Indicator | UTG | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 46.00 | 56.71 |
| Support Level | $35.87 | $194.44 |
| Resistance Level | $36.99 | $202.97 |
| Average True Range (ATR) | 0.57 | 5.93 |
| MACD | 0.01 | 0.84 |
| Stochastic Oscillator | 47.25 | 81.22 |
Reaves Utility Income Fund is a closed-end management investment company. The company's investment objective is to provide a high level of after-tax income and total return consisting of tax-advantaged dividend income and capital appreciation. It invests a portion of its total assets in securities of utility companies, which may include companies in the electric, gas, water, telecommunications sectors, as well as other companies engaged in other infrastructure operations.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.